Anthony M. Manning

CIK: 0001716468

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)1 (25.0%)

Position reduction

Option Exercises (M)1 (25.0%)

Derivative conversions

Awards (A)2 (50.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

GLUE

Monte Rosa Therapeutics, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (4 total)

GLUE
Monte Rosa Therapeutics, Inc.
Jun 11, 2026
Award(A)
Stock Option (Right to Buy)
Direct
25.8K shares-
GLUE
Monte Rosa Therapeutics, Inc.
May 21, 2026
Exercise(M)
Direct
10K shares at avg. $4.16$42K
GLUE
Monte Rosa Therapeutics, Inc.
May 21, 2026
Sale(S)
Direct
10K shares at avg. $18.01$180K
GLUE
Monte Rosa Therapeutics, Inc.
Jun 13, 2025
Award(A)
Stock Option (Right to Buy)
Direct
30.7K shares-

		Type	Shares	Price		Ownership
Jun 11, 2026	GLUE Monte Rosa Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	25,800	-	-	Direct
May 21, 2026	GLUE Monte Rosa Therapeutics, Inc.	Exercise(M)	10,000	$4.16	$41,600	Direct
May 21, 2026	GLUE Monte Rosa Therapeutics, Inc.	Sale(S)	10,000	$18.01	$180,100	Direct
Jun 13, 2025	GLUE Monte Rosa Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	30,700	-	-	Direct

1-4 of 4 transactions

About Manning Anthony M.

Manning Anthony M. (SEC CIK 0001716468) files insider reports with the SEC as Director of Monte Rosa Therapeutics, Inc. (GLUE).

Signal8 holds 3 ownership filings by Manning Anthony M., all Form 4s, filed between Jun 16, 2025 and Jun 12, 2026. Those filings report 4 transactions, from Jun 13, 2025 to Jun 11, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Manning Anthony M.'s filings is in BOSTON, MA.

Recent filings by Manning Anthony M.

Jun 11, 2026: Grant or award of GLUE derivative securities (Form 4, code A).
May 21, 2026: Option exercise of GLUE shares (Form 4, code M).
May 21, 2026: Open-market sale of GLUE shares (Form 4, code S).
Jun 13, 2025: Grant or award of GLUE derivative securities (Form 4, code A).

Other insiders filing for Monte Rosa Therapeutics, Inc. (GLUE)

Bowen Matthew, Principal Accounting Officer
Warmuth Markus, President & CEO
Champoux Jennifer, Chief Operating Officer
Townson Sharon, Chief Scientific Officer
Behbahani Ali, Director
Janku Filip, Chief Medical Officer

How to read Form 4 transaction codes